Lintel Trio Tablet is a combination antihypertensive medication containing Telmisartan 40mg, Cilnidipine 10mg, and Chlorthalidone 12.5mg, formulated to effectively manage hypertension. Telmisartan, an angiotensin II receptor blocker (ARB), acts by inhibiting the vasoconstrictive effects of angiotensin II, thereby reducing blood pressure and providing cardiovascular protection. Cilnidipine, a calcium channel blocker with dual action on L-type and N-type calcium channels, promotes vasodilation and decreases peripheral vascular resistance, contributing to improved blood flow and blood pressure control. Chlorthalidone, a thiazide-like diuretic, facilitates sodium and water excretion, reducing plasma volume and further aiding in blood pressure reduction. The combined pharmacological actions of these agents provide a comprehensive approach to hypertension management, targeting different physiological pathways to achieve optimal blood pressure control. Lintel Trio Tablet is indicated for patients requiring multi-mechanistic therapy for hypertension, particularly those inadequately controlled with monotherapy or dual therapy. It should be used under medical supervision, with monitoring of renal function, electrolytes, and blood pressure to minimize potential adverse effects such as hypotension, electrolyte imbalance, or renal impairment. This combination therapy offers improved compliance by reducing pill burden while ensuring effective and sustained antihypertensive action.